About
ICONS is a non-profit organization whose mission is to boost research impacts on society via public communication, business and social innovation. Since more than 25 years ICONS is a key partner in EU-funded R&I projects. ICONS designs and executes communication, dissemination, exploitation, business and social innovation strategies and measures their impacts through innovative indicators. ICONS has been successfully involved in more than 100 EU-funded projects and in different service contracts for the European Commission. In recent years, ICONS has played a key role as advisor and strategic consultant for the EC and other EU agencies. Among others, it is one of the partners of the BOOSTER consortium, the EU flagship initiative delivering dissemination and exploitation support services to R&I projects funded in FP7, H2020 and Horizon Europe.
Areas of Activity
IHI Topic 1: IHI European healthcare incubator networkIHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studiesIHI Topic 3: Decode the immuno-science of age-related mediated diseasesHORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatmentHORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancersHORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypesHORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes researchHORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicinesHORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agenciesOther